chemXplore tracks 9 projects in Argentina, of which 5 are active.
Of the active ones, 3 new construction and 2 expansion.
Craig makes safety his first priority after two recent site fatalities, flags FY2026 results (US$33bn EBITDA; US$13bn profit), confirms Jansen first production mid next year and 3–4% CAGR to 2035.
Proforma gearing at a historic low of 9% and adjusted CFFO lifted to €16.5bn; underlying E&P output +7% to 1.83 mln boe/d. Strategic deals include Junin 5 relaunch and asset monetisations.
Upstream work finished at a 4,000 m Argentina site, raising commercial carbonate output to 48,000 t/year and enabling a 50,000 t/year lithium hydroxide system when linked to a 2027 downstream plant.
Meeting covered cooperation on gas development via floating liquefaction; Argentina LNG targets 12 MTPA initially, investment decision due end of year and start-up planned for 2030.
Argentina targets global LNG supply; first phase 12 Mtpa from Vaca Muerta with YPF and Eni partnership, promising over 40,000 jobs and export revenues.
Once‑daily oral GLP‑1 cut MACE vs insulin glargine, lowered A1C by 1.6% at 52 weeks and produced mean weight loss of 8.1 kg with durable effects to 104 weeks.
Combination achieved up to 23.3% weight loss (54.1 lbs) and 2.9% A1C reduction versus 14.8% (34.4 lbs) and 2.4% with tirzepatide; Phase 3 to start Q4 2026.
An indirect, covariate‑adjusted comparison of SURMOUNT‑1 and STEP UP data shows larger mean and categorical weight‑loss benefits with tirzepatide 10 mg and 15 mg at 72 weeks.
FDA clears once‑weekly basal insulin that reduces injection frequency vs daily therapy; Phase 3 QWINT trials in >3,400 adults showed non‑inferior A1C vs glargine and degludec.
APF multidose preservative‑free pump line commissioned to serve Latin American markets, cutting lead times and improving local supply agility.
